New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PCYC;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 27, 2015
07:59 EDTPCYCPharmacyclics risk/reward unappealing, says Bernstein
Subscribe for More Information
06:56 EDTPCYCPharmacyclics downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
February 26, 2015
18:06 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Goldman
Subscribe for More Information
10:00 EDTPCYCOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
09:41 EDTJNJHospira launches generic Remicade, WSJ says
Subscribe for More Information
09:03 EDTPCYCPharmacyclics price target raised to $240 from $200 at RW Baird
Subscribe for More Information
08:03 EDTJNJJohnson & Johnson forms new health and wellness platform
Subscribe for More Information
06:52 EDTJNJ, PCYCPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTJNJ, PCYCPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTJNJ, PCYCPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
14:02 EDTPCYCPharmacyclics downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
13:30 EDTPCYCPharmacyclics calls active on exploring options reports
Pharmacyclics March 220 and April 230 calls are active on total call volume of 4,200 contracts (3,100 puts) on exploring options including sale, Bloomberg reports. Active call volume suggests traders taking positions for upside price movement.
12:54 EDTJNJ, PCYCPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJ, PCYCPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
12:50 EDTPCYCPharmacyclics jumps 19% after Bloomberg says weighing sale
Subscribe for More Information
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use